Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

MyNCBI Filters
Text availability
Article attribute
Article type
Publication date

Search Results

110 results
Filters applied: . Clear all Results are displayed in a computed author sort order. Results by year timeline is unavailable
Page 1
Genome-wide CRISPR-Cas9 screening reveals ubiquitous T cell cancer targeting via the monomorphic MHC class I-related protein MR1.
Crowther MD, Dolton G, Legut M, Caillaud ME, Lloyd A, Attaf M, Galloway SAE, Rius C, Farrell CP, Szomolay B, Ager A, Parker AL, Fuller A, Donia M, McCluskey J, Rossjohn J, Svane IM, Phillips JD, Sewell AK. Crowther MD, et al. Among authors: Parker AL. Nat Immunol. 2020 Feb;21(2):178-185. doi: 10.1038/s41590-019-0578-8. Epub 2020 Jan 20. Nat Immunol. 2020. PMID: 31959982
Author Correction: Genome-wide CRISPR-Cas9 screening reveals ubiquitous T cell cancer targeting via the monomorphic MHC class I-related protein MR1.
Crowther MD, Dolton G, Legut M, Caillaud ME, Lloyd A, Attaf M, Galloway SAE, Rius C, Farrell CP, Szomolay B, Ager A, Parker AL, Fuller A, Donia M, McCluskey J, Rossjohn J, Svane IM, Phillips JD, Sewell AK. Crowther MD, et al. Among authors: Parker AL. Nat Immunol. 2020 Mar 2. doi: 10.1038/s41590-020-0640-6. Online ahead of print. Nat Immunol. 2020. PMID: 32123375
Evidence for contribution of CD4+ CD25+ regulatory T cells in maintaining immune tolerance to human factor IX following perinatal adenovirus vector delivery.
Nivsarkar MS, Buckley SM, Parker AL, Perocheau D, McKay TR, Rahim AA, Howe SJ, Waddington SN. Nivsarkar MS, et al. Among authors: Parker AL. J Immunol Res. 2015;2015:397879. doi: 10.1155/2015/397879. Epub 2015 Jan 31. J Immunol Res. 2015. PMID: 25759840 Free PMC article.
Ad5NULL-A20: A Tropism-Modified, αvβ6 Integrin-Selective Oncolytic Adenovirus for Epithelial Ovarian Cancer Therapies.
Uusi-Kerttula H, Davies JA, Thompson JM, Wongthida P, Evgin L, Shim KG, Bradshaw A, Baker AT, Rizkallah PJ, Jones R, Hanna L, Hudson E, Vile RG, Chester JD, Parker AL. Uusi-Kerttula H, et al. Among authors: Parker AL. Clin Cancer Res. 2018 Sep 1;24(17):4215-4224. doi: 10.1158/1078-0432.CCR-18-1089. Epub 2018 May 24. Clin Cancer Res. 2018. PMID: 29798908
Capsid modification strategies for detargeting adenoviral vectors.
Parker AL, Bradshaw AC, Alba R, Nicklin SA, Baker AH. Parker AL, et al. Methods Mol Biol. 2014;1089:45-59. doi: 10.1007/978-1-62703-679-5_3. Methods Mol Biol. 2014. PMID: 24132476
Incorporation of Peptides Targeting EGFR and FGFR1 into the Adenoviral Fiber Knob Domain and Their Evaluation as Targeted Cancer Therapies.
Uusi-Kerttula H, Legut M, Davies J, Jones R, Hudson E, Hanna L, Stanton RJ, Chester JD, Parker AL. Uusi-Kerttula H, et al. Among authors: Parker AL. Hum Gene Ther. 2015 May;26(5):320-9. doi: 10.1089/hum.2015.015. Hum Gene Ther. 2015. PMID: 25919378 Free PMC article.
Precision virotherapies: Coming soon.
Uusi-Kerttula H, Parker AL. Uusi-Kerttula H, et al. Among authors: Parker AL. Oncotarget. 2018 Nov 2;9(86):35605-35606. doi: 10.18632/oncotarget.26280. eCollection 2018 Nov 2. Oncotarget. 2018. PMID: 30479689 Free PMC article. No abstract available.
110 results
Jump to page
Feedback